The Scottish Medicines Consortium (SMC) has rejected rimonobant (Acomplia®) for use on the NHS in Scotland.
The recommendation states that the economic case has not been demonstrated although it also indicates that a resubmission is likely.
Rimonobant has already been identified as having a lower place in therapy by the Midlands Therapeutic Review and Advisory Committee and it was previously recommended as a fourth line option when it was launched.
Action: Until an economic case is demonstrated it would be sensible to restrict prescribing of rimonobant to patients who have already started treatment and are achieving weight loss.
|« Insulin Discontinuation brought forward||GOLD and GINA updates »|